FIELD NOTE
Intuitive will pay $450 million to settle the hospital repair case. On the same call, it said it will extend the life of the instruments the case was about.
Intuitive disclosed on October 20 that it had agreed to settle In re Da Vinci Surgical Robot Antitrust Litigation for a one-time payment of $450 million plus what the company calls mutually agreed injunctive relief, reached after an October mediation and carrying no admission of liability. The charge landed in third-quarter selling, general and administrative expenses: $347 million net of tax, 99 cents a share, cutting GAAP net income to $523 million on revenue of $3.05 billion. The settlement still needs preliminary and final court approval, and CFO Jamie Samath told analysts the company does not expect a decision until next year.
The case was never about robots. Entities that bought da Vinci service and EndoWrist instruments in the United States between May 21, 2017 and the end of 2021 — the class Judge Araceli Martínez-Olguín certified in March 2025, under both the damages and the injunctive-relief provisions of Rule 23 — alleged that Intuitive tied the machine to its own service contract, barred independent repair and self-servicing, and capped each EndoWrist at roughly ten uses by means of a counter inside the instrument, forcing replacement purchases it controlled. Tying, exclusive dealing, monopolization. The district court had already held in March 2024 that the robot and the instruments are separate products, then vacated its own findings on Intuitive’s power in the instrument aftermarket four months later, reading the Ninth Circuit’s Epic Games decision to require that a single-brand aftermarket’s restrictions be unknown to buyers at the time of purchase. Intuitive’s restrictions were in the signed contracts.
Then that reading collapsed. On August 13 the Ninth Circuit reversed a judgment in Intuitive’s favor in a parallel case brought by Surgical Instrument Service, the company that marketed a counter-reset service for used EndoWrists. Writing for the panel, Judge Lucy Koh held that the Kodak and Epic lock-in factors apply only where a plaintiff cannot show the defendant has power in the foremarket. SIS put in evidence that Intuitive held more than 99 percent of the US market for minimally invasive surgical robots and all of the EndoWrist aftermarket, which makes it an ordinary foremarket-to-aftermarket tying case with no lock-in showing required. The error, the court said, infected every claim, and a jury could also find Intuitive’s process for approving third-party products and services illusory. That is the rule the Federal Trade Commission had asked the court to adopt a year earlier, in a brief supporting neither party: the lock-in factors “have no role to play when there is no meaningful competition in the foremarket.”
So the class settles and the doctrine hardens. SIS goes back to the district court with live claims and an appellate rule that makes the aftermarket theory materially easier to run against any manufacturer with a dominant installed base. Intuitive had 12,094 da Vinci systems in the field at the end of September.
Which is the context for the other thing management said on that call. Samath told analysts the company will extend the useful lives of a subset of core EndoWrist instruments beginning in the first half of 2027, pending a 510(k) that is in process, and that this plus a China price reduction will lower da Vinci instrument and accessory revenue per procedure by roughly 3 to 5 percent on a mix-constant basis. He framed it as a deliberate choice to broaden adoption in high-volume benign procedures where cost is a barrier.
Read it that way and it is a growth decision. Read the docket and it is the use counter, loosened, in the same quarter the company agreed to pay $450 million to end a case about the use counter. Intuitive has not said the two are connected, the injunctive terms are not public, and CEO David Rosa described the agreement as a no-fault settlement that “provides certainty for both our customers and Intuitive.”
The transferable part is not the money. It is that an aftermarket built on a consumable limit, a captive service contract and a company-run approval process for third parties is now a litigable structure rather than a commercial one, and the Ninth Circuit just lowered the cost of testing it. Any device company whose plan assumes the blades earn more than the handle should price that in before someone else does it for them.
SPONSORED BY RŌG HEALTH
A full commercial team for your next milestone.
No hiring required.
A raise, a launch, or a first hospital contract takes more than a good device. It takes messaging that holds up, investor and sales materials, a website, training, and regulatory and manufacturing partners who all understand where the company is headed. Most teams either try to hire for all of it before the milestone or piece it together from vendors who never talk to each other.
RŌG Health gives you that team now. We start with where you’re headed and what’s in the way. Then we bring our own people and a bench of partner firms in regulatory, manufacturing, and commercial execution, all working from the same plan and telling the same story. When the work is done, it adds up to one company instead of six deliverables.
If your next milestone needs more than your current team can carry, book 30 minutes with the RŌG Health team.
Want to put your brand in front of 28,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.